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AbsTrACT
Objective To validate the estimates of Global Burden 
of Disease (GBD) due to congenital anomaly for 
Europe by comparing infant mortality data collected by 
EUROCAT registries with the WHO Mortality Database, 
and by assessing the significance of stillbirths and 
terminations of pregnancy for fetal anomaly (TOPFA) in 
the interpretation of infant mortality statistics.
Design, setting and outcome measures EUROCAT 
is a network of congenital anomaly registries collecting 
data on live births, fetal deaths from 20 weeks’ gestation 
and TOPFA. Data from 29 registries in 19 countries were 
analysed for 2005–2009, and infant mortality (deaths 
of live births at age <1 year) compared with the WHO 
Mortality Database. Eight EUROCAT countries were 
excluded from further analysis on the basis that this 
comparison showed poor ascertainment of survival status.
results According to WHO, 17%–42% of infant 
mortality was attributed to congenital anomaly. In 
11 EUROCAT countries, average infant mortality with 
congenital anomaly was 1.1 per 1000 births, with higher 
rates where TOPFA is illegal (Malta 3.0, Ireland 2.1). 
The rate of stillbirths with congenital anomaly was 0.6 
per 1000. The average TOPFA prevalence was 4.6 per 
1000, nearly three times more prevalent than stillbirths 
and infant deaths combined. TOPFA also impacted on 
the prevalence of postneonatal survivors with non-lethal 
congenital anomaly.
Conclusions By excluding TOPFA and stillbirths 
from GBD years of life lost (YLL) estimates, GBD 
underestimates the burden of disease due to congenital 
anomaly, and thus declining YLL over time may obscure 
lack of progress in primary, secondary and tertiary 
prevention.
InTrODuCTIOn
According to the 2010 Global Burden of Disease 
(GBD) study,1 2 congenital anomalies accounted for 
510 400 deaths worldwide in 2010, 1% of all deaths 
(6% of neonatal and postneonatal infant deaths, 
2.5% of deaths 1–4 years), ranking 23rd among 
all causes of death.1 Since deaths due to congenital 
anomaly tend to be very early in life,3 the burden 
in years of life lost (YLL) is higher — congenital 
anomaly ranked 14th among causes of death.1
The GBD estimates were based on the WHO 
Mortality Database,4 for which death certification 
is the major data source. For low-income/middle-in-
come countries, they are likely to be underestimated 
due to the absence of accurate cause of death data5 6 
— Modell et al have calculated that mortality due to 
congenital anomaly for the under-5 age group is likely 
to be a fourfold underestimation,6 and have proposed 
that better mortality estimates would be produced 
by combining prevalence estimates with estimated 
survival in different healthcare systems. Further 
caveats in interpreting GBD statistics for congen-
ital anomaly are that stillbirths and terminations of 
What is already known on this topic?
 ► Global Burden of Disease (GBD) estimates of 
years of life lost due to congenital anomaly 
have been declining over time worldwide.
 ► GBD estimates include only live births.
 ► It is difficult to obtain accurate cause of death 
data from death certificates for infant and child 
deaths.
What this study adds?
 ► EUROCAT data (2005–2009) show terminations 
of pregnancy for congenital anomaly were 
almost three times more frequent than infant 
deaths and stillbirths with congenital anomaly 
combined.
 ► In countries where termination of pregnancy 
is illegal, the rate of infant mortality with 
congenital anomaly is higher than in other 
European countries.
 ► Ignoring termination of pregnancy and 
stillbirth underestimates the GBD associated 
with congenital anomaly and obscures lack 
of progress in primary, secondary and tertiary 
prevention.
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pregnancy for fetal anomaly (TOPFA) after prenatal diagnosis are 
not counted among deaths. The practice of civil registration of 
perinatal deaths due to severe or lethal congenital anomaly as still-
births or very early neonatal deaths can vary in time and place due 
to differences in registration practices7 and in resuscitation prac-
tices at the edge8 of viability.8–10 Thus it is illogical to count deaths 
in the first week of life in GBD, but not stillbirths.
EUROCAT is a network of population-based congenital 
anomaly registries in Europe covering approximately 30% of the 
European Union (EU) birth population as well as some non-EU 
countries. Prevalence data11 are based on a well-validated, 
harmonised system.12 The aims of this paper are to compare 
infant mortality data collected by EUROCAT registries with 
that provided in the WHO Mortality Database, and to discuss 
the significance of stillbirths and TOPFA in the interpretation 
of infant mortality statistics. In Europe, TOPFA is legal in all 
countries represented in EUROCAT, except Ireland and Malta.
MeThODs
The EUROCAT central database contains standard data on 
congenital anomaly cases from population-based congenital 
anomaly registries.12–14 Cases include live births, fetal deaths 
from 20 weeks’ gestation (including stillbirths) and TOPFA (of 
any gestational age). Survival (yes/no) to 1 week (days 0–6) is 
recorded for all liveborn cases by all registries. Age at death (in 
days) is also available for 29 registries in 19 countries, at least 
up to age 1 year, but may not be complete as many registries 
do not have access to death certificates.13 These 29 registries 
include two associate registries (Finland and Sweden), which 
provided aggregate data regarding survival but do not contribute 
individual data to the central database. In the 19 countries, 
3%–100% of national births are covered by EUROCAT regis-
tries (table 1).
For ascertainment of survival, 9 out of 29 registries have 
systematic access to death certificates (table 1); 9 have system-
atic access to hospital notes up to at least 1 year; 2 registries have 
systematic access to hospital notes up to 1 week or discharge; 
and 8 out of 29 have no systematic data source.
The WHO Mortality Database4 includes the total number 
of deaths under 1 year (infant deaths) by cause of death. Still-
births are not included. Numbers of all infant deaths and infant 
deaths due to congenital anomaly were downloaded for the 
years 2005–2009, by country, for all countries participating in 
EUROCAT (table 1). The population for which both WHO 
and EUROCAT data were available (at the time of download) 
comprised 2715 012 live births. Infant mortality recorded by 
EUROCAT is slightly differently defined — deaths of registered 
cases are recorded, but the cause of death (which is not recorded) 
may occasionally not be related to the congenital anomaly, and 
we therefore refer to this as ‘deaths of infants with congenital 
anomaly’.
WHO rates per 1000 births of ‘infant death/mortality due 
to congenital anomaly’ for the entire country were compared 
with EUROCAT rates per 1000 births of ‘infant death/mortality 
with congenital anomaly’ for the portion of the country covered 
by EUROCAT. WHO data are based on year of death while 
EUROCAT data are based on year of birth. The comparison (and 
all further analyses of EUROCAT data) was based on years (of 
death/birth) present in both databases. There were 11 EUROCAT 
countries (19 registries) that recorded rates of infant mortality 
with congenital anomaly of 80% or more than the rate recorded 
by WHO (figure 1), thus indicating that coverage of deaths up 
to 1 year was reasonably complete. Data from 17 registries in 
9 of these countries (ie, excluding Finland and Sweden) were 
included in further analyses of pregnancy outcome and age at 
death.
EUROCAT records all major congenital anomalies, excluding 
a specified list of minor anomalies and conditions that are poorly 
specified or related to immaturity at birth.12 Major congen-
ital anomalies for this paper were classified into subgroups 
according to EUROCAT Guide 1.312 based on International 
Classificationf or Diseases (ICD) codes, further classified by 
isolated/multiply malformed/syndrome status according to the 
EUROCAT multiple malformation algorithm.15 For this paper, 
cases were also grouped according to chances of survival: lethal 
anomalies (anencephaly, bilateral renal agenesis, trisomy 13 and 
18), anomalies associated with TOPFA (Down syndrome, spina 
bifida, analysed separately) and anomalies usually liveborn and 
requiring surgery16 17 (severe congenital heart defects, digestive 
system anomalies, abdominal wall defects, craniosynostosis and 
orofacial clefts).
Analyses included prevalence per 1000 births/live births of 
infant deaths with congenital anomaly, proportion of infant 
deaths among live births by age at death and prevalence of 
congenital anomaly cases from ‘all diagnosed cases’ including 
TOPFA, to all cases surviving to 20 weeks (ie, excluding 
TOPFA <20 weeks), to birth (live birth or stillbirth or late fetal 
death from 20 weeks’ gestation), to live birth, to age 1 week, 28 
days and 1 year.
Perinatal death/mortality is here defined as all fetal deaths 
from 20 weeks’ gestation (including stillbirths) and first-week 
deaths, expressed per 1000 total births; infant mortality: deaths 
at age <1 year per 1000 live births; early neonatal mortality: 
first week deaths per 1000 live births; late neonatal mortality: 
deaths from 7 days to 27 days per 1000 live births; and post-
neonatal mortality: deaths from 1 month to 1 year per 1000 
live births.
This research is in compliance with the Helsinki Declaration 
(http://www. wma. net/ en/ 30publications/ 10policies/ b3/ index. 
html). Permission for the study as part of the EUROCAT project 
was granted by the Institute of Nursing and Health Research, 
School of Nursing Research Governance Filter Committee 
at Ulster University on behalf of the Ulster University Ethics 
Committee.
resulTs
According to the WHO data, 17%–43% of infant mortality was 
attributed to congenital anomaly, with higher attributable rates 
recorded in Malta (43%) and Ireland (42%) (table 1).
After excluding the eight EUROCAT countries with poor 
survival data (infant mortality with congenital anomaly more 
than 20% lower than recorded by WHO), there remained seven 
countries where EUROCAT estimates were between 80% and 
100% of the WHO rate, in six of which some of the difference 
may be explained by geographical non-representativeness. In 
four countries, EUROCAT estimates were higher than WHO. 
The greatest differences were in Finland, where WHO mortality 
was 0.92 per 1000 but the EUROCAT estimate (with 100% 
national coverage) was 29% higher at 1.19 per 1000 (table 1), 
and Ireland, where WHO mortality was 1.63 but the EUROCAT 
estimate (with 62% national coverage) was 26% higher at 2.05 
per 1000 (table 1). The average (EUROCAT) infant mortality 
with congenital anomaly in the 11 analysed countries was 1.1 
per 1000 (figure 2).
The average total prevalence of congenital anomaly cases 
(including live births, fetal deaths more than 20 weeks and 
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TOPFA) in the 11 countries was 26.9 per 1000 births. Of these 
77.0% were live births surviving infancy.
A total of 17% of congenital anomaly cases were TOPFA, 
or a prevalence of 4.6 per 1000 births (figure 2), varying from 
0 (Malta) to 7.5 per 1000 (Spain-Basque Country) (figure 2). 
A total of 2.1% were stillbirths, a prevalence of 0.6 per 1000 
births, also varying by country (figure 2). Early neonatal 
deaths accounted for 49% of all first-year deaths. The preva-
lence of perinatal deaths and infant deaths was higher in those 
countries where TOPFA is illegal (figure 2). In Ireland 10.6% 
of all congenital anomaly cases were perinatal deaths, and 
in Malta 8.9%. Ukraine differed from the other countries in 
having relatively high perinatal and infant mortality in spite of 
having a TOPFA rate at the lower end of the range (figure 2). 
Spain-Basque Country had the highest overall mortality 
(figure 2), most of this being due to TOPFA, and lowest peri-
natal mortality.
Overall, TOPFA was four times more common than infant 
deaths and nearly three times more common than all stillbirths 
and infant deaths combined (figure 2). Infant mortality was 
highest for multiply malformed live births (15% of cases) and 
lowest for cases with an isolated anomaly (nearly 4%, figure 3).
The survival pattern and prevalence of survivors at 1 year differs 
between countries where TOPFA is legal and illegal (figure 4). For 
lethal anomalies, the prevalence of survivors converges at 1 week of 
life between countries where TOPFA is legal and illegal (figure 4). 
For Down syndrome and spina bifida, where TOPFA is frequent 
but infant mortality is low, the difference between countries where 
TOPFA is legal and illegal is greatest and persists up to 1 year of life 
(figure 4). For congenital anomaly typically liveborn and requiring 
Figure 1 Prevalence per 1000 live births of infant deaths due to congenital anomaly (WHO) and infant deaths with congenital anomaly (EUROCAT) 
for 29 EUROCAT registries in 19 countries, 2005–2009. *Registries and years as stated in Table 1.
Figure 2 Prevalence per 1000 births of infant deaths with congenital 
anomaly, by age at death and country, for 19 EUROCAT registries in 
11 countries, 2005–2009. *TOPFA, terminations of pregnancy for fetal 
anomaly. *Years as stated in Table 1. Eleven countries (19 EUROCAT 
Registries) which ascertain more than 80% of the infant mortality 
attributed to congenital anomaly recorded by WHO: Austria = Styria; 
Belgium = Antwerp and Hainaut; Denmark = Odense; Finland; Ireland 
=Dublin, SE Ireland and Cork & Kerry; Malta; Northern Netherlands; 
Spain = Basque Country, Sweden; UK= Wales, SW England, Wessex, 
Northern England, EMSYCAR and Thames Valley; Ukraine.
Figure 3 Proportion of infant deaths among live births with 
congenital anomaly, by age at death, and association with multiple 
malformations or syndromes, for 17 EUROCAT registries in nine 
countries, 2005–2009. *Years as stated in Table 1. Nine countries (17 
full member EUROCAT registries) which ascertain more than 80% of 
the infant mortality attributed to congenital anomaly recorded by WHO:  
Austria = Styria; Belgium = Antwerp and Hainaut;  Denmark = Odense; 
Ireland = Dublin, SE Ireland and Cork & Kerry; Spain = Basque Country; 
UK = Wales, SW England, Wessex, Northern England, EMSYCAR and 
Thames Valley;  Ukraine.  *Years as stated in Table 1.
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surgery, the survival pattern converges at 1 year of age in the two 
groups of countries (figure 4).
Among all TOPFAs, 42% were at 20 weeks’ gestational age or 
later, varying according to anomaly category (figure 4).
Thirty-five per cent of babies (live or still) with lethal anom-
alies were stillborn (figure 4), as against 4%–9% for the other 
categories (figure 4). Infants with lethal anomalies accounted for 
16% of all recorded infant mortality with a congenital anomaly 
and infants with surgically treatable anomalies 52%.
DIsCussIOn
Infant mortality due to congenital anomaly in Europe, 
according to the WHO mortality data based on death certifi-
cates, ranges from one-fifth to two-fifths of infant deaths. Strat-
egies to reduce infant mortality due to congenital anomaly are 
therefore an important part of meeting the millennium goals 
to reduce infant mortality18 and the sustainable development 
goals for 2030,19 and we need accurate and comprehensive 
data to monitor progress. We found that EUROCAT national 
estimates of infant mortality could be up to 29% higher than 
WHO estimates based on death certificates alone, assumed to 
be mainly cases where congenital anomaly had not been given 
as the primary cause of death on death certificates. On the other 
hand, we also found evidence of under-recording of mortality 
by some EUROCAT congenital anomaly registries that was 
unlikely to be explained by limitations of the extrapolation of 
regional to national data. Congenital anomaly registries should 
be adequately resourced for, and data protection legislation 
should allow, their role in establishing fundamental population 
health statistics.
EUROCAT data show that TOPFA is on average four times 
more frequent than infant deaths, and nearly three times more 
frequent than stillbirths and infant deaths combined. Infant 
mortality due to congenital anomaly in a country is higher when 
the prevalence of TOPFA is lower, and it follows that increases 
over time in the TOPFA rate would lower the infant mortality 
rate. There is a danger then that apparent improvements in 
infant mortality due to congenital anomaly (and associated 
YLL) in GBD estimates could, via exclusion of TOPFA, mask 
lack of progress in primary prevention,20 lack of improvement 
in tertiary prevention via surgery5 and/or lack of improvement 
in secondary prevention via early diagnosis (prenatally or post-
natally), leading to more successful treatment.21 This may be 
leading to misinterpretation of GBD statistics, such as the fall in 
YLL between 1990 and 2010.1 2 In addition, the current GBD 
estimates omit any appropriate weighting of the disability asso-
ciated with loss of wanted pregnancies.
In Europe in the last 30 years, little progress has been made 
towards primary prevention of congenital anomalies, and this has 
occasioned EUROCAT to issue recommendations to encourage 
integrated primary prevention policies.22 Although periconcep-
tional folic acid is a known protective factor for neural tube 
defects, evidence to date shows that neural tube defect preva-
lence has not declined23 due to failure of public health policy and 
implementation. It has only been possible to bring this to light by 
Figure 4 Prevalence of congenital anomaly cases per 1000 births, from before 20 weeks’ pregnancy up to 1 year of age, by legality of TOPFA* for 
lethal anomalies, Down syndrome, spina bifida, and surgically treated anomalies, for 17 EUROCAT registries in nine countries,** 2005–2009.*** 
*TOPFA is illegal in Malta and Ireland. **Nine countries (15 full EUROCAT registries)  which ascertain more than 80% of the infant mortality 
attributed to congenital anomaly recorded by WHO:  Austria = Styria; Belgium = Antwerp and Hainaut;  Denmark = Odense; Ireland = Dublin, SE 
Ireland and Cork & Kerry; Malta; Northern Neterlands; Spain = Basque Country; UK = Wales, SW England, Wessex, Northern England, EMSYCAR 
and Thames Valley;  Ukraine. ***years as stated in Table 1 ^Lethal anomalies are anencephaly, bilateral renal agenesis and trisomy 13 and 
18^^Anomalies typically requiring surgery are: severe congenital heart defects, digestive system anomalies, abdominal wall defects, craniosynostosis 
and oro-facial clefts. See Public Health Indicators Khoshnood et al (8) all diagnosed cases” including TOPFA, to all cases surviving to 20 weeks (i.e. 
excluding TOPFA <20 weeks), to birth (livebirth or stillbirth or late fetal death from 20 weeks gestation), to livebirth, to age one week, 28 days and 1 
year.
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including data on TOPFA in surveillance, showing that increases 
in TOPFA have led to decreases in live birth prevalence, but that 
there has been no overall change in total prevalence.23
The exclusion of stillbirths from GBD burden of disease esti-
mates has the greatest impact for lethal congenital anomalies. 
We had too few data to examine differences in civil registration 
(recording the birth of a baby with lethal anomaly as live or still) 
between countries, but this is likely10 for sociocultural and health 
system reasons.
For conditions such as spina bifida and Down syndrome with 
low postnatal mortality,24 our data show an impact of TOPFA on 
the prevalence of survivors and thus on Disability Adjusted Life 
Year (DALYs)25 rather than on YLLs. Investment in health and 
social services should reflect the greater needs in countries with 
lower TOPFA rates.
For surgically treatable anomalies (selected indicator condi-
tions excluding spina bifida16), we found that the prevalence of 
survivors converges at 1 year, indicating that TOPFAs concerns 
the more severe cases with higher risk of mortality. Euro-
pean infant mortality for these conditions was much less than 
described for low-income and middle-income countries,5 and 
given the importance of improving surgical treatment in these 
countries, we suggest that separate monitoring of surgically 
treatable congenital anomaly be undertaken. Prenatal diagnosis 
may also be improving outcomes for these conditions,26 for 
postnatal surgery and increasingly also fetal surgery. In Europe 
on average, these anomalies represent at least 52% of all infant 
deaths with congenital anomaly.
Higher infant mortality due to congenital anomaly should be 
expected in countries where TOPFA is illegal,27 and socioeco-
nomic differences within countries may occur where prenatal 
diagnosis or TOPFA is linked to ability to pay.28 29 However, 
there are some problems in the interpretation of data. There is 
evidence that, in those countries where abortion is illegal, some 
women are travelling abroad for TOPFA.30 On the other hand, 
we slightly overestimated the impact of TOPFA on mortality, 
since some early TOPFA (of the 58% under 20 weeks’ gesta-
tion) may without intervention have resulted in a spontaneous 
abortion by 20 weeks. From 10 weeks’ gestation, 89% Down 
syndrome, 77% trisomy 18 and 73% of trisomy 13 are estimated 
to survive to 20 weeks’ gestation31 while survival is higher for 
non-chromosomal conditions and from later gestational ages.
The majority (77% in our data) of children with congenital 
anomalies in the developed world are liveborn and survive 
infancy often with significant disability and need for treatment 
and rehabilitative services. The full burden of disease requires 
assessment of DALYs.25 The validity of the disability weighting 
system for congenital anomalies32 used in GBD requires further 
examination.6 Almost all the DALYs currently attributed to 
congenital anomalies in GBD estimates are related to early death 
rather than disability.25
The strengths of this paper are the broad geographical 
coverage and the high quality of case data recorded, including 
all pregnancy outcomes (except miscarriages before 20 weeks) 
and well-validated diagnoses. We analysed mortality as preva-
lence per 1000 births rather than proportion of all congenital 
anomaly cases, because proportions can be affected by variable 
ascertainment of live births diagnosed after the early neonatal 
period. The main limitation of interpretation is extrapolation 
from regional registries to a national scale for comparison with 
the WHO estimates, where there may be economic, social 
or healthcare differences between regions.26 We classified a 
limited number of conditions as ‘lethal’, although this term has 
been criticised and its application found to be variable in the 
literature,32 and we found a small number of deaths later than 
1 year among ‘lethal’ conditions. Our case categories were based 
on EUROCAT Public Health Indicators,16 which do not include 
all congenital anomalies and make certain case classification 
decisions, such as analysing spina bifida on its own rather than 
included in surgically treatable anomalies, which could affect 
comparability with other studies.
COnClusIOns
GBD currently only considers the deaths of liveborn congen-
ital anomaly cases and excludes TOPFA and stillbirths. This 
underestimates the societal health impact. TOPFA distorts both 
YLL and DALY estimates. Awareness of these issues is crucial in 
interpreting changes in GBD estimates in relation to primary, 
secondary or tertiary prevention.
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